PCSK9 inhibitor valuation: A science-based review of the two recent models.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Alirocumab 4 endocrinologydiseasesdrugs
Evolocumab 1 endocrinologydiseasesdrugs
ezetimibe 3 endocrinologydiseasesdrugs
familial hypercholesterolemia 2 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Alirocumab 6861 phase 2 and 3 studies such as the ODYSSEY trials: LONG TERM (Long‐term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their
Alirocumab 7034 Not Adequately Controlled with Their Lipid Modifying Therapy), FH I and II (Efficacy and Safety of Alirocumab [SAR236553/REGN727] Versus Placebo on Top of Lipid‐Modifying Therapy in Patients With Heterozygous
Alirocumab 7273 Hypercholesterolemia Not Adequately Controlled With Their Lipid‐Modifying Therapy), HIGH FH (Efficacy and Safety of Alirocumab [SAR236553/REGN727] Versus Placebo on Top of Lipid‐Modifying Therapy in Patients With Heterozygous
Alirocumab 7453 Therapy in Patients With Heterozygous Familial Hypercholesterolemia); and COMBO 1 (Efficacy and Safety of Alirocumab [SAR236553/REGN727] Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia),
Evolocumab 8221 EVOLOCUMAB, WHAT ARE THE INDICATIONS3In 2015, the FDA approved the PCSK9 mabs alirocumab and evolocumab. Evolocumab received approval for homozygous FH, whereas both drugs were approved for heterozygous FH and clinical
ezetimibe 12553 convincing demonstration of the lack of safety concerns. It also acknowledged that other drugs, such as ezetimibe , can reduce CV events by lowering LDL‐C as seen in the IMPROVE IT (Examining Outcomes in Subjects
ezetimibe 14446 no prior intervention when added to statins has reduced mortality, not high‐intensity statins or ezetimibe , or most recently anacetrapib.8, 40, 41 Only when compared with placebo have statins shown a mortality
ezetimibe 17899 this gentleman had a persistent LDL‐C well over 200 mg/dL on maximally tolerated statin therapy, ezetimibe , and a bile acid sequestrant.28 He was an indisputable candidate for a PCSK9 mab. Yet it took a year
Select Disease Character Offset Disease Term Instance
familial hypercholesterolemia 2732 pathogenic/cholesterol connection lagged.2 Then, in 1939, Carl Müller identified the first cases of familial hypercholesterolemia (FH), introducing genetics as a participant in cholesterol regulation.3 His patients had extremely high
familial hypercholesterolemia 5492 role of the LDL receptor.7 Their model helped clinicians and scientists not only better understand familial hypercholesterolemia (FH), but also pursue more appropriate therapeutics to lower LDL‐C and thereby diminish ASCVD risk.

You must be authorized to submit a review.